Back to results
US 2022/0054495 A1Published application
Compositions and methods for enhanced delivery of antiviral agents
AssigneePoviva Corp.
InventorsJohn Docherty, Christopher Andrew Bunka
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods, compositions and kits for treating a viral infection, for example, COVID-19, MERS and SARS. The disclosed compositions provide for enhanced delivery of the disclosed antiviral agents.
Claims31
A pharmaceutical composition, comprising:
- a) from about 25 mg to about 300 mg by weight of one or more antiviral agents or a pharmaceutically acceptable salt thereof;
- and
- b) from about 50 mg to about 600 mg by weight of a bioavailability enhancing agent.
A pharmaceutical composition, comprising:
- a) an effective amount of one or more antiviral agents chosen from amprenavir (or the pro-drug fosamprenavir), atazanavir, boceprevir, darunavir, indinavir, lopinavir, nelfmavir, ritonavir, saquinavir, simeprevir, telaprevir, or tipranavir, doravirine, efavirenz, etravirine, loviride, rilpivirine, cobicistat, baloxavir marboxil, bictegravir, elvitegravir, daclatasvir, maraviroc, umifenovir, methisazone, tromantadine, rimantadine, GS-441524, remdesivir, sarilumab, indinavir, raltegravir, nevirapine, or azidothymidine;
- and
- b) sunflower oil;
- and
- c) gum arabic.
2 more elements
Dependencies are inferred from the claim text.